Drug Search Results
More Filters [+]

Clesacostat

Alternative Names: clesacostat, pf-05221304, pf05221304, pf 05221304
Latest Update: 2024-09-18
Latest Update Note: News Article

Product Description

an investigational acetyl-CoA carboxylase inhibitor (ACCi) (Sourced from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline)

Mechanisms of Action: ACC Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Hepatitis|Hepatitis, Alcoholic|Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Clesacostat

Countries in Clinic: Bulgaria, Canada, China, India, Japan, Korea, Poland, Puerto Rico, Slovakia, Taiwan, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Non-alcoholic Steatohepatitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C3711005

P2

Completed

Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis

2022-03-31

CTR20210412

P2

Not yet recruiting

Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis

None

Recent News Events